<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;ff=20250130170937&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;ff=20250130170937&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 30 Jan 2025 22:09:38 +0000</lastbuilddate>
<pubDate>Wed, 29 Jan 2025 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Reply: Recurrent Ischemic Stroke After PFO Closure: Unconsidered Low RoPE Score and Thrombophilia</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39880554/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250130170937&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Feb 4;85(4):e65. doi: 10.1016/j.jacc.2024.11.036.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39880554/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250130170937&v=2.18.0.post9+e462414">39880554</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.036>10.1016/j.jacc.2024.11.036</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39880554</guid>
<pubDate>Wed, 29 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Kasper Bonnesen</dc:creator>
<dc:creator>Asger Andersen</dc:creator>
<dc:creator>Claus Ziegler Simonsen</dc:creator>
<dc:creator>Jens Erik Nielsen-Kudsk</dc:creator>
<dc:creator>Morten Schmidt</dc:creator>
<dc:date>2025-01-29</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Recurrent Ischemic Stroke After PFO Closure: Unconsidered Low RoPE Score and Thrombophilia</dc:title>
<dc:identifier>pmid:39880554</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.036</dc:identifier>
</item>
<item>
<title>Recurrent Ischemic Stroke After PFO Closure: Unconsidered Low RoPE Score and Thrombophilia</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39880553/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250130170937&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Feb 4;85(4):e63. doi: 10.1016/j.jacc.2024.10.122.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39880553/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250130170937&v=2.18.0.post9+e462414">39880553</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.122>10.1016/j.jacc.2024.10.122</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39880553</guid>
<pubDate>Wed, 29 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Anastasios Apostolos</dc:creator>
<dc:creator>Maria Drakopoulou</dc:creator>
<dc:creator>Konstantinos Tsioufis</dc:creator>
<dc:creator>Konstantinos Toutouzas</dc:creator>
<dc:date>2025-01-29</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Recurrent Ischemic Stroke After PFO Closure: Unconsidered Low RoPE Score and Thrombophilia</dc:title>
<dc:identifier>pmid:39880553</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.122</dc:identifier>
</item>
<item>
<title>Expanding the Dialogue on Atrial Fibrillation in the United States</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39880552/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250130170937&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Feb 4;85(4):e61. doi: 10.1016/j.jacc.2024.11.038.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39880552/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250130170937&v=2.18.0.post9+e462414">39880552</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.038>10.1016/j.jacc.2024.11.038</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39880552</guid>
<pubDate>Wed, 29 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Connor G Oltman</dc:creator>
<dc:creator>Taehyung P Kim</dc:creator>
<dc:creator>James W Y Lee</dc:creator>
<dc:creator>John D Lupu</dc:creator>
<dc:creator>Issam D Moussa</dc:creator>
<dc:date>2025-01-29</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Expanding the Dialogue on Atrial Fibrillation in the United States</dc:title>
<dc:identifier>pmid:39880552</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.038</dc:identifier>
</item>
<item>
<title>Reply: What Is the Diagnostic and Prognostic Value of the Electrocardiographic QRS Attenuation in Myocarditis?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39880551/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250130170937&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Feb 4;85(4):e59. doi: 10.1016/j.jacc.2024.11.037.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39880551/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250130170937&v=2.18.0.post9+e462414">39880551</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.037>10.1016/j.jacc.2024.11.037</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39880551</guid>
<pubDate>Wed, 29 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Benedikt Bernhard</dc:creator>
<dc:creator>Christoph Gräni</dc:creator>
<dc:date>2025-01-29</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: What Is the Diagnostic and Prognostic Value of the Electrocardiographic QRS Attenuation in Myocarditis?</dc:title>
<dc:identifier>pmid:39880551</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.037</dc:identifier>
</item>
<item>
<title>What Is the Diagnostic and Prognostic Value of the Electrocardiographic QRS Attenuation in Myocarditis?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39880550/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250130170937&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Feb 4;85(4):e57. doi: 10.1016/j.jacc.2024.10.123.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39880550/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250130170937&v=2.18.0.post9+e462414">39880550</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.123>10.1016/j.jacc.2024.10.123</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39880550</guid>
<pubDate>Wed, 29 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>John E Madias</dc:creator>
<dc:date>2025-01-29</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>What Is the Diagnostic and Prognostic Value of the Electrocardiographic QRS Attenuation in Myocarditis?</dc:title>
<dc:identifier>pmid:39880550</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.123</dc:identifier>
</item>
<item>
<title>Reply: Plasma Triglyceride Reduction and Cardiovascular Risk in ODYSSEY Outcomes Trial: Interpret With Caution</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39880549/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250130170937&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Feb 4;85(4):e55. doi: 10.1016/j.jacc.2024.11.039.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39880549/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250130170937&v=2.18.0.post9+e462414">39880549</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.039>10.1016/j.jacc.2024.11.039</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39880549</guid>
<pubDate>Wed, 29 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Doron Zahger</dc:creator>
<dc:creator>Gregory G Schwartz</dc:creator>
<dc:creator>Michael Szarek</dc:creator>
<dc:creator>Sergio Fazio</dc:creator>
<dc:creator>P Gabriel Steg</dc:creator>
<dc:date>2025-01-29</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Plasma Triglyceride Reduction and Cardiovascular Risk in ODYSSEY Outcomes Trial: Interpret With Caution</dc:title>
<dc:identifier>pmid:39880549</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.039</dc:identifier>
</item>
<item>
<title>Plasma Triglyceride Reduction and Cardiovascular Risk in ODYSSEY Outcomes Trial: Interpret With Caution</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39880548/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250130170937&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Feb 4;85(4):e53-e54. doi: 10.1016/j.jacc.2024.10.124.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39880548/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250130170937&v=2.18.0.post9+e462414">39880548</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.124>10.1016/j.jacc.2024.10.124</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39880548</guid>
<pubDate>Wed, 29 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Chris J Packard</dc:creator>
<dc:creator>Jan Borén</dc:creator>
<dc:creator>M John Chapman</dc:creator>
<dc:date>2025-01-29</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Plasma Triglyceride Reduction and Cardiovascular Risk in ODYSSEY Outcomes Trial: Interpret With Caution</dc:title>
<dc:identifier>pmid:39880548</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.124</dc:identifier>
</item>
<item>
<title>Amara Yad Image: The Mitral Valve, Aortic Root, and Aortomitral Continuity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39880547/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250130170937&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Feb 4;85(4):389-390. doi: 10.1016/j.jacc.2024.12.016.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39880547/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250130170937&v=2.18.0.post9+e462414">39880547</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.12.016>10.1016/j.jacc.2024.12.016</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39880547</guid>
<pubDate>Wed, 29 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Kalyanam Shivkumar</dc:creator>
<dc:date>2025-01-29</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Amara Yad Image: The Mitral Valve, Aortic Root, and Aortomitral Continuity</dc:title>
<dc:identifier>pmid:39880547</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.12.016</dc:identifier>
</item>
<item>
<title>Transforming Publishing: Your Paper, Your Way at JACC</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39880546/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250130170937&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Feb 4;85(4):386-388. doi: 10.1016/j.jacc.2024.12.015.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39880546/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250130170937&v=2.18.0.post9+e462414">39880546</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.12.015>10.1016/j.jacc.2024.12.015</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39880546</guid>
<pubDate>Wed, 29 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Harlan M Krumholz</dc:creator>
<dc:date>2025-01-29</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Transforming Publishing: Your Paper, Your Way at JACC</dc:title>
<dc:identifier>pmid:39880546</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.12.015</dc:identifier>
</item>
<item>
<title>Highlights from the 2024 Annual Meeting of the ESC Working Group on Myocardial and Pericardial Diseases in Athens</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39880401/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250130170937&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 30:ehae831. doi: 10.1093/eurheartj/ehae831. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39880401/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250130170937&v=2.18.0.post9+e462414">39880401</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae831>10.1093/eurheartj/ehae831</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39880401</guid>
<pubDate>Wed, 29 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>organizing committee of the 2024 Annual Meeting of the ESC Working Group on Myocardial and Pericardial Diseases</dc:creator>
<dc:date>2025-01-29</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Highlights from the 2024 Annual Meeting of the ESC Working Group on Myocardial and Pericardial Diseases in Athens</dc:title>
<dc:identifier>pmid:39880401</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae831</dc:identifier>
</item>
<item>
<title>Default Bulk Ordering and Text Messaging to Enhance Outreach for Lipid Screening: A Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39879069/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250130170937&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Lipid screening among participants receiving bulk orders and outreach letters increased significantly compared with usual care at 3 months. However, there was no difference at 6 months. More than 80% of patients did not follow through with lipid screening despite the intervention, and there was no additional increase in lipid testing at 3 months among participants receiving bulk ordering and supplemental text messaging.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Jan 29. doi: 10.1001/jamacardio.2024.5281. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: A comprehensive lipid panel is recommended by guidelines to evaluate atherosclerotic cardiovascular disease risk, but uptake is low.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To evaluate whether direct outreach including bulk orders with and without text messaging increases lipid screening rates.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: Pragmatic randomized clinical trial conducted from June 6, 2023, to September 6, 2023, at 2 primary care practices at an academic health system among patients aged 20 to 75 years with at least 1 primary care visit in the past 3 years who were overdue for lipid screening. Data analysis was performed from September 2023 to May 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Eligible patients were randomized in a 1:2:2 ratio to usual care (group 1), direct outreach and bulk orders (group 2), and bulk order outreach with additional text message reminders for scheduling assistance (group 3). In group 3, participants received an initial, follow-up, and reminder text message. Patients with electronic portal accounts were encouraged to schedule through them, while others received laboratory contact information. Any participant inquiries were answered either with automated responses for common questions or with study team support.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Proportion of patients who completed a lipid panel within 3 months.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among the 1000 participants, the median (IQR) age was 38 (28-55) years; 470 (47.0%) were female; and 22 (2.3%) were Asian, 38 (3.9%) were Black, 32 (3.2%) were Hispanic or Latino, and 862 (88.6%) were White (race and ethnicity were based on self-reported data). At 3 months, a lipid panel was completed by 12 of 202 patients (5.9%; 95% CI, 3.4% to 10.1%) receiving usual care (group 1) vs 62 of 394 patients (15.7%; 95% CI, 12.5% to 19.7%) receiving direct outreach and bulk order (group 2), a difference of 9.8 percentage points (95% CI, 4.6 to 15.0; P = .001). The panel was completed by 73 of 404 patients (18.1%; 95% CI, 14.6% to 22.1%) receiving outreach, bulk order, and text message reminders (group 3), for a difference of 2.4 percentage points (95% CI, -3.1 to 7.8; P = .43) vs outreach with bulk order alone (group 2). At 6 months, there were no significant differences in lipid screening between either group 1 vs group 2 or group 2 vs group 3.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Lipid screening among participants receiving bulk orders and outreach letters increased significantly compared with usual care at 3 months. However, there was no difference at 6 months. More than 80% of patients did not follow through with lipid screening despite the intervention, and there was no additional increase in lipid testing at 3 months among participants receiving bulk ordering and supplemental text messaging.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05724615.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39879069/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250130170937&v=2.18.0.post9+e462414">39879069</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.5281>10.1001/jamacardio.2024.5281</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39879069</guid>
<pubDate>Wed, 29 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Catherine Pollak</dc:creator>
<dc:creator>Andrew Parambath</dc:creator>
<dc:creator>Samantha Coratti</dc:creator>
<dc:creator>Laurie Norton</dc:creator>
<dc:creator>Anthony Girard</dc:creator>
<dc:creator>Catherine Reitz</dc:creator>
<dc:creator>Christopher K Snider</dc:creator>
<dc:creator>Lin Xu</dc:creator>
<dc:creator>Zakiya Walker</dc:creator>
<dc:creator>Aileen John</dc:creator>
<dc:creator>Mary E Putt</dc:creator>
<dc:creator>Kevin G Volpp</dc:creator>
<dc:creator>Shivan J Mehta</dc:creator>
<dc:date>2025-01-29</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Default Bulk Ordering and Text Messaging to Enhance Outreach for Lipid Screening: A Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:39879069</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.5281</dc:identifier>
</item>
<item>
<title>Error in Byline</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39878992/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250130170937&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Jan 29. doi: 10.1001/jamacardio.2024.5630. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39878992/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250130170937&v=2.18.0.post9+e462414">39878992</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.5630>10.1001/jamacardio.2024.5630</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39878992</guid>
<pubDate>Wed, 29 Jan 2025 06:00:00 -0500</pubDate>
<dc:date>2025-01-29</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Error in Byline</dc:title>
<dc:identifier>pmid:39878992</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.5630</dc:identifier>
</item>
<item>
<title>Treatment Strategies to Control Blood Pressure in People With Hypertension in Tanzania and Lesotho: A Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39878989/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250130170937&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Results of this randomized clinical trial show that in 2 African settings, for adults with uncomplicated untreated hypertension, a strategy starting a 2-pill low-dose treatment was noninferior to starting stepped monotherapy. Two-pill and 3-pill low-dose strategies were not superior to stepped monotherapy. Wide CIs preclude the ability to rule out potentially clinically important effects of the additional pill strategies for hypertension control.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Jan 29. doi: 10.1001/jamacardio.2024.5124. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Hypertension is the primary cardiovascular risk factor in Africa. Recently revised World Health Organization guidelines recommend starting antihypertensive dual therapy; clinical efficacy and tolerability of low-dose triple combination remain unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: To compare the effect of 3 treatment strategies on blood pressure control among persons with untreated hypertension in Africa.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was an open-label, parallel, 3-arm randomized clinical trial to evaluate noninferiority of a strategy starting 2 pills vs full-dose monotherapy with stepped escalation (noninferiority margin 10%) and superiority of starting low-dose 3 pills vs monotherapy allowing for monthly up titration. Recruitment lasted from March 5, 2020, to March 30, 2022. The setting was 2 hospitals in rural Lesotho and Tanzania. Participants included nonpregnant Black African individuals 18 years and older with uncomplicated, untreated hypertension (standardized office blood pressure ≥140 mm Hg systolic or ≥90 mm Hg diastolic).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Participants were randomized 2:2:1 to stepped monotherapy (amlodipine, 10 mg, with escalation to add hydrochlorothiazide if needed), 2-pill strategy (amlodipine, 5 mg; losartan, 25 mg), or 3-pill strategy (amlodipine, 2.5 mg; losartan, 12.5 mg; hydrochlorothiazide, 6.25 mg). Drugs were up titrated monthly until reaching the target blood pressure (≤ 130/80 mm Hg for participants aged &lt;65 years; ≤140/90 mm Hg for those aged ≥65 years).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Proportion of participants reaching target blood pressure at 12 weeks.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 1761 participants screened, 1268 were enrolled (median [IQR] age, 54 [45-65] years; 914 female [72%]), with 505 in the monotherapy cohort, 510 in the 2-pill cohort, and 253 in the 3-pill cohort. In noninferiority analyses, 207 of 370 participants (56%) receiving the 2-pill strategy and 173 of 338 participants (51%) receiving the stepped monotherapy strategy achieved the blood pressure target (adjusted odds ratio [aOR], 1.18; 95% CI, 0.87-1.61), fulfilling noninferiority. In superiority analyses after multiple imputation for missing outcome data, 57% of participants receiving the 3-pill strategy, 55% receiving the 2-pill strategy, and 49% receiving the stepped monotherapy strategy reached the target blood pressure (aOR, 1.24; 95% CI, 0.94-1.63; P = .12 and aOR, 1.28; 95% CI, 0.91-1.79; P = .16 for the 2-pill and 3-pill vs stepped monotherapy strategies, respectively).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Results of this randomized clinical trial show that in 2 African settings, for adults with uncomplicated untreated hypertension, a strategy starting a 2-pill low-dose treatment was noninferior to starting stepped monotherapy. Two-pill and 3-pill low-dose strategies were not superior to stepped monotherapy. Wide CIs preclude the ability to rule out potentially clinically important effects of the additional pill strategies for hypertension control.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04129840.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39878989/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250130170937&v=2.18.0.post9+e462414">39878989</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.5124>10.1001/jamacardio.2024.5124</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39878989</guid>
<pubDate>Wed, 29 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Herry Mapesi</dc:creator>
<dc:creator>Martin Rohacek</dc:creator>
<dc:creator>Fiona Vanobberghen</dc:creator>
<dc:creator>Ravi Gupta</dc:creator>
<dc:creator>Herieth Ismael Wilson</dc:creator>
<dc:creator>Blaise Lukau</dc:creator>
<dc:creator>Alain Amstutz</dc:creator>
<dc:creator>Aza Lyimo</dc:creator>
<dc:creator>Josephine Muhairwe</dc:creator>
<dc:creator>Elizabeth Senkoro</dc:creator>
<dc:creator>Theonestina Byakuzana</dc:creator>
<dc:creator>Jacqueline Nkouabi</dc:creator>
<dc:creator>Geofrey Mbunda</dc:creator>
<dc:creator>Jamali Siru</dc:creator>
<dc:creator>Ayesha Tarr</dc:creator>
<dc:creator>Elsie Ramapepe</dc:creator>
<dc:creator>Madavida Mphunyane</dc:creator>
<dc:creator>Johanna Oehri</dc:creator>
<dc:creator>Valeriya Nemtsova</dc:creator>
<dc:creator>Xiaohan Yan</dc:creator>
<dc:creator>Moniek Bresser</dc:creator>
<dc:creator>Tracy Renée Glass</dc:creator>
<dc:creator>Daniel Henry Paris</dc:creator>
<dc:creator>Günther Fink</dc:creator>
<dc:creator>Winfrid Gingo</dc:creator>
<dc:creator>Niklaus Daniel Labhardt</dc:creator>
<dc:creator>Thilo Burkard</dc:creator>
<dc:creator>Maja Weisser</dc:creator>
<dc:date>2025-01-29</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Treatment Strategies to Control Blood Pressure in People With Hypertension in Tanzania and Lesotho: A Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:39878989</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.5124</dc:identifier>
</item>
<item>
<title>The '10 commandments' for the 2024 European Society of Cardiology guidelines on atrial fibrillation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39878965/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250130170937&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 29:ehae847. doi: 10.1093/eurheartj/ehae847. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39878965/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250130170937&v=2.18.0.post9+e462414">39878965</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae847>10.1093/eurheartj/ehae847</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39878965</guid>
<pubDate>Wed, 29 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Dipak Kotecha</dc:creator>
<dc:creator>Michiel Rienstra</dc:creator>
<dc:creator>Isabelle C Van Gelder</dc:creator>
<dc:date>2025-01-29</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The '10 commandments' for the 2024 European Society of Cardiology guidelines on atrial fibrillation</dc:title>
<dc:identifier>pmid:39878965</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae847</dc:identifier>
</item>
<item>
<title>Working towards a flourishing work environment as a legacy for future generations</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39878964/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250130170937&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 29:ehae849. doi: 10.1093/eurheartj/ehae849. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39878964/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250130170937&v=2.18.0.post9+e462414">39878964</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae849>10.1093/eurheartj/ehae849</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39878964</guid>
<pubDate>Wed, 29 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Julia Grapsa</dc:creator>
<dc:creator>Niya Mileva</dc:creator>
<dc:date>2025-01-29</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Working towards a flourishing work environment as a legacy for future generations</dc:title>
<dc:identifier>pmid:39878964</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae849</dc:identifier>
</item>
<item>
<title>Blood Pressure Control-Many Paths, 1 Goal</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39878963/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250130170937&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Jan 29. doi: 10.1001/jamacardio.2024.5278. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39878963/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250130170937&v=2.18.0.post9+e462414">39878963</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.5278>10.1001/jamacardio.2024.5278</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39878963</guid>
<pubDate>Wed, 29 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Erica S Spatz</dc:creator>
<dc:creator>Jeremy I Schwartz</dc:creator>
<dc:creator>Thomas R Frieden</dc:creator>
<dc:date>2025-01-29</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Blood Pressure Control-Many Paths, 1 Goal</dc:title>
<dc:identifier>pmid:39878963</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.5278</dc:identifier>
</item>
<item>
<title>The ESC Scientific Documents Committee: purposes and achievements</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39878962/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250130170937&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 29:ehae913. doi: 10.1093/eurheartj/ehae913. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39878962/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250130170937&v=2.18.0.post9+e462414">39878962</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae913>10.1093/eurheartj/ehae913</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39878962</guid>
<pubDate>Wed, 29 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Stefan James</dc:creator>
<dc:date>2025-01-29</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The ESC Scientific Documents Committee: purposes and achievements</dc:title>
<dc:identifier>pmid:39878962</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae913</dc:identifier>
</item>
<item>
<title>Introducing The Lancet Regional Health-Europe commission on inequalities and disparities in cardiovascular health</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39878143/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250130170937&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 29:ehae793. doi: 10.1093/eurheartj/ehae793. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39878143/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250130170937&v=2.18.0.post9+e462414">39878143</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae793>10.1093/eurheartj/ehae793</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39878143</guid>
<pubDate>Wed, 29 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Raffaele Bugiardini</dc:creator>
<dc:creator>Chris P Gale</dc:creator>
<dc:creator>Martha Gulati</dc:creator>
<dc:date>2025-01-29</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Introducing The Lancet Regional Health-Europe commission on inequalities and disparities in cardiovascular health</dc:title>
<dc:identifier>pmid:39878143</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae793</dc:identifier>
</item>
<item>
<title>Anthracycline-induced cardiomyopathy: risk prediction, prevention and treatment</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39875555/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250130170937&amp;v=2.18.0.post9+e462414
      <description>Anthracyclines are the cornerstone of treatment for many malignancies. However, anthracycline cardiotoxicity is a considerable concern given that it can compromise the clinical effectiveness of the treatment and patient survival despite early discontinuation of therapy or dose reduction. Patients with cancer receiving anthracycline treatment can have a reduction in their quality of life and likelihood of survival due to cardiotoxicity, irrespective of their oncological prognosis. Increasing...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2025 Jan 28. doi: 10.1038/s41569-025-01126-1. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Anthracyclines are the cornerstone of treatment for many malignancies. However, anthracycline cardiotoxicity is a considerable concern given that it can compromise the clinical effectiveness of the treatment and patient survival despite early discontinuation of therapy or dose reduction. Patients with cancer receiving anthracycline treatment can have a reduction in their quality of life and likelihood of survival due to cardiotoxicity, irrespective of their oncological prognosis. Increasing knowledge about anthracycline cardiotoxicity has enabled the identification of patients who are candidates for anthracycline regimens and those who might develop anthracycline-induced cardiomyopathy. Anthracycline cardiotoxicity is a unique and evolving phenomenon that begins with myocardial cell damage, progresses to reduced left ventricular ejection fraction, and culminates in symptomatic heart failure if it is not promptly detected and treated. Early risk stratification can be guided by imaging or biomarkers. In this Review, we present a comprehensive and clinically useful approach to cardiomyopathy related to anthracycline therapy, encompassing its epidemiology, definition, mechanisms, novel classifications, risk factors and patient risk stratification, diagnostic approaches (including imaging and biomarkers), treatment guidelines algorithms, and the role of new cardioprotective drugs that are used for the treatment of heart failure.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39875555/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250130170937&v=2.18.0.post9+e462414">39875555</a> | DOI:<a href=https://doi.org/10.1038/s41569-025-01126-1>10.1038/s41569-025-01126-1</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39875555</guid>
<pubDate>Tue, 28 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Iacopo Fabiani</dc:creator>
<dc:creator>Michela Chianca</dc:creator>
<dc:creator>Carlo Maria Cipolla</dc:creator>
<dc:creator>Daniela Maria Cardinale</dc:creator>
<dc:date>2025-01-28</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Anthracycline-induced cardiomyopathy: risk prediction, prevention and treatment</dc:title>
<dc:identifier>pmid:39875555</dc:identifier>
<dc:identifier>doi:10.1038/s41569-025-01126-1</dc:identifier>
</item>
<item>
<title>The molecular structure of LDL has finally been elucidated</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39875554/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250130170937&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2025 Jan 28. doi: 10.1038/s41569-025-01128-z. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39875554/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250130170937&v=2.18.0.post9+e462414">39875554</a> | DOI:<a href=https://doi.org/10.1038/s41569-025-01128-z>10.1038/s41569-025-01128-z</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39875554</guid>
<pubDate>Tue, 28 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Gilles C Lambert</dc:creator>
<dc:creator>Simon G Pfisterer</dc:creator>
<dc:date>2025-01-28</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>The molecular structure of LDL has finally been elucidated</dc:title>
<dc:identifier>pmid:39875554</dc:identifier>
<dc:identifier>doi:10.1038/s41569-025-01128-z</dc:identifier>
</item>
<item>
<title>Obesity alters cholesterol homeostasis in regulatory T cells of visceral adipose tissue</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39875553/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250130170937&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2025 Jan 28. doi: 10.1038/s41569-025-01129-y. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39875553/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250130170937&v=2.18.0.post9+e462414">39875553</a> | DOI:<a href=https://doi.org/10.1038/s41569-025-01129-y>10.1038/s41569-025-01129-y</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39875553</guid>
<pubDate>Tue, 28 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Irene Fernández-Ruiz</dc:creator>
<dc:date>2025-01-28</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Obesity alters cholesterol homeostasis in regulatory T cells of visceral adipose tissue</dc:title>
<dc:identifier>pmid:39875553</dc:identifier>
<dc:identifier>doi:10.1038/s41569-025-01129-y</dc:identifier>
</item>





























</channel>
</rss>